Wang Wei, Liao Zhong-Kai, Hu Sheng-Shou, Song Yun-Hu, Huang Jie
Department of Cardiac Surgery, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy Science and Peking Union Medical College, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Nov;37(11):1014-7.
To summarize and analyze clinical outcomes and experience about using extracorporeal membrane oxygenation (ECMO) in supporting heart transplant patients in the peri-operative period of in Fuwai Hospital retrospectively.
We performed 131 orthotopic heart transplantations from June 2004 to December 2008. Fourteen cases used veno-artery ECMO (Medtronic Ltd) for mechanical circulatory support in the peri-operative period of heart transplantation. Active clotting time(ACT) was maintained between 160 - 200 seconds, mean blood flow was 1.8 - 3.3 L/min during ECMO assistant period.
Twelve survivals discharged with NYHAI, two patients died of multiple orgen failure with severe infection and complication of central nervous system. The ECMO time was 75 - 824 h and mean time 149 h. 12 survivals with ECMO assistance decreases the dose of vasoactive drugs, after bedside UCG evaluating heart function recovery with stable circulation, ECMO could be weaned off uneventfully after 100 h. Five patients with seven times bleeding complication and one patient with catheter-associated arterial thrombosis of distal limb, all ECMO patients with low-albuminemia and hyperbilirubinemia at some degree, eleven patients with increasing blood creatine and five patients were treated with continous renal replacement therapy, one patient with pertinacious hyperbilirubinemia was treated with plasma exchange and molecular absorbent recirculating system. Seven patients were extension incision healing and six patients were tracheotomy.
ECMO can bridge patients with end-stage heart failure to heart transplant, and extend the use of marginal donors, grasp the ECMO indication and timing of application, avoiding irreversible dysfunction of the vital organs and preventing complication during ECMO, ECMO may decrease mortality of severe patients in the peri-operative period of heart transplantation.
回顾性总结和分析阜外医院在心脏移植患者围手术期应用体外膜肺氧合(ECMO)的临床疗效及经验。
2004年6月至2008年12月共进行131例原位心脏移植手术。其中14例在心脏移植围手术期应用静脉-动脉ECMO(美敦力公司)进行机械循环支持。在ECMO辅助期间,活化凝血时间(ACT)维持在160 - 200秒,平均血流量为1.8 - 3.3升/分钟。
12例存活患者出院时心功能为纽约心脏协会(NYHA)Ⅰ级,2例患者死于多器官功能衰竭伴严重感染及中枢神经系统并发症。ECMO支持时间为75 - 824小时,平均时间为149小时。12例存活患者在ECMO辅助下减少了血管活性药物的剂量,经床旁超声心动图评估心功能恢复且循环稳定后,100小时后可顺利撤机。5例患者发生7次出血并发症,1例患者发生远端肢体导管相关动脉血栓形成,所有ECMO患者均有不同程度的低白蛋白血症和高胆红素血症,11例患者血肌酐升高,5例患者接受持续肾脏替代治疗,1例顽固性高胆红素血症患者接受血浆置换和分子吸附再循环系统治疗。7例患者切口延期愈合,6例患者行气管切开术。
ECMO可为终末期心力衰竭患者过渡到心脏移植提供支持,并扩大边缘供体的使用范围,掌握ECMO的适应证和应用时机,避免重要器官发生不可逆功能障碍并预防ECMO期间的并发症,ECMO可降低心脏移植围手术期重症患者的死亡率。